|Day Low/High||32.58 / 33.07|
|52 Wk Low/High||27.59 / 55.79|
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the National Institute for Health and Care Excellence (NICE) in England has recommended CINQAERO ® (reslizumab) in its Final Appraisal...
AstraZeneca shares rose after the group said its CEO would host an earnings call later this month following speculation he was to take up a similar role Teva Pharmaceuticals.
Rumors swirled that Pascal Soriot would leave for rival Teva Pharmaceuticals.
CEO Pascal Soriot may be on his way to Israel's Teva Pharmaceuticals ahead of key drug trial information release.
Neither company has confirmed Pascal Soriot's move.
European benchmarks held gains much of Thursday.
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced that all proposals were approved at its Annual General Meeting of Shareholders held earlier today.
AstraZeneca shares dropped in the first hours of trading Thursday after it was reported that Teva Pharmaceuticals was courting its CEO.
AstraZeneca CEO Pascal Sorio will reportedly take over at Teva.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it will release its second quarter 2017 financial results on Thursday, August 3, 2017 at 6:30 a.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) and the Huntington Study Group today announced results from the Phase III open-label, single-arm switch cohort of the ARC-HD ( Alternatives for Reducing Chorea in...
Lilly sued Actavis, saying its generic product would still infringe on Lilly's vitamin regimens regardless of any dilution.
Oklahoma Attorney General Mike Hunter alleged that the firms engaged in misleading marketing practices and "waged a fraudulent, decade-long marketing campaign to profit from the anguish of thousands of Oklahomans."
Celltrion, Inc., a global biopharmaceutical company, and Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the publication of results from the Phase III study, AIM-TD ( A ddressing I nvoluntary M ovements in T ardive D yskinesia), in the...
Technology might be about to change the healthcare industry forever, or at least according to Teva Pharmaceutical's CEO.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Xenon Pharmaceuticals Inc.
Positive subscription trends and less downside risk this year have the company well positioned, Mizuho says.
Individual state investigations of opioid marketing practices has lead to a multistate investigation of the prescription painkiller industry.
Generic drugmakers are likely to limit themselves to acquisitions of small- and mid-sized companies in the immediate future because of over-leveraging and turmoil in the executive ranks..
Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of generic Zetia ®1 (ezetimibe) tablets, 10 mg, in the U.